Clinical ResearchEditorial CommentNoncompliance and Cessation of Dual Antiplatelet Therapy After Coronary Stenting: Looking at the Speck Rather Than Noticing the Log?∗
Editorial Comment
Under an Elsevier user license
open archive
Key Words
aspirin
cessation
compliance
coronary artery disease
Cited by (0)
Dr. Biondi-Zoccai has served on advisory boards for Bayer; has consulted for Novartis; and has lectured for Abbott Vascular, AstraZeneca, Bayer, and St. Jude Medical. Dr. Abbate has served on advisory boards for Janssen; has lectured for Grifols; and has received research support from Novartis. Dr. Frati has reported that he has no relationships relevant to the contents of this paper to disclose.
- ∗
Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.